{"id":4727,"date":"2025-10-06T14:15:02","date_gmt":"2025-10-06T11:15:02","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4727"},"modified":"2025-10-06T14:51:39","modified_gmt":"2025-10-06T11:51:39","slug":"zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd\/","title":{"rendered":"Zydus Lifesciences, DMD&#039;yi Tedavi Etmek \u0130\u00e7in Deflazacort&#039;ye Y\u00f6nelik FDA Onay\u0131 Ald\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">6 Ekim Pazartesi g\u00fcn\u00fc, ila\u00e7 \u015firketi Zydus Lifesciences, FDA&#039;nin 22,75 mg\/mL dozda deflazacort oral s\u00fcspansiyonu i\u00e7in nihai onay\u0131 verdi\u011fini duyurdu. \u00dcr\u00fcn, jenerik formda 22,75 mg\/mL Emflaza oral s\u00fcspansiyon i\u00e7ermektedir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Deflazacort (Emflaza) nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne Musk\u00fcler Distrofisi (DMD) olan be\u015f ya\u015f ve \u00fczeri hastalar deflazacort oral s\u00fcspansiyon ile tedavi edilebilir. Steroid s\u0131n\u0131f\u0131n\u0131n bir \u00fcyesi olan bu ila\u00e7, iltihab\u0131 azaltmaya ve a\u015f\u0131r\u0131 tepki veren ba\u011f\u0131\u015f\u0131kl\u0131k sistemini sakinle\u015ftirmeye yard\u0131mc\u0131 olur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Zydus&#039;a g\u00f6re \u00fcr\u00fcn \u0130talya&#039;n\u0131n Doppel kentinde \u00fcretilecek. Bu onayla birlikte grubun toplam onay say\u0131s\u0131 424&#039;e ula\u015ft\u0131.<\/p>","protected":false},"excerpt":{"rendered":"<p>On Monday, October 6, pharmaceutical company Zydus Lifesciences announced that the FDA has given its final approval for its oral suspension of deflazacort at a dose of 22.75 mg\/mL. The product contains 22.75 mg\/mL of Emflaza oral suspension in a generic form. What is Deflazacort (Emflaza)? Patients five years of age and older with Duchenne [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4728,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[211,428,88,429],"class_list":["post-4727","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-deflazacort","tag-emflaza","tag-fda","tag-zydus-lifesciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4727"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4727\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4728"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}